An introduction to conducting discrete choice experiments in healthcare
Wednesday 26 June, 9.30am
We are very pleased to welcome Dr James Buchanan, Senior Lecturer at Queen Mary University of London, to present our next ISPOR NZ webinar: An introduction to conducting discrete choice experiments in healthcare.
It is becoming increasingly important to have a good understanding of choice behaviour in health settings. For example, understanding why people might select one treatment over another, or why people might undertake activities that carry health risks, or why people choose not to vaccinate newborns against common childhood illnesses. Quantitative data on the preferences that underpin these choice behaviours can be generated using an approach called a discrete choice experiment (DCE). Such data is increasingly being used alongside evidence on cost-effectiveness to guide the efficient allocation of scarce healthcare resources. However, a DCE will only yield high quality data on preferences if it has been carefully designed, undertaken, and analysed.
In this webinar, James will provide a practical step-by-step guide to conducting a DCE in healthcare. All stages will be covered, from selecting attributes and levels, to experimental design, to data collection and analysis and interpretation. Case studies will be presented from different clinical contexts, including genomic medicine and the use of antibiotics. The webinar will be targeted at those who are working towards undertaking their first DCE, and there will time allocated for a Q&A session following the main presentation.
The webinar will be held at 9:30am on Wednesday 26 June. For details and registration, please see the event sign-up page.
About the speaker
Dr James Buchanan is a Senior Lecturer in Health Economics at Queen Mary University of London (QMUL) in the UK. At QMUL James leads on work on the health economic aspects of precision diagnosis and treatment and translation research, across the Barts Biomedical Research Centre. His research focuses on applying economic methods to quantify the value of precision medicine for stakeholders in the health system. He has a particular interest in understanding the costs and benefits of genome sequencing in people with cancer and rare diseases, in particular newborns. He has undertaken and published economic evaluations, outcomes studies, microcosting analyses, and discrete choice experiments in this space, working alongside national population sequencing initiatives such as the Genomics England 100,000 Genomes Project. He also curates the Health Economics and Genomics blog. Prior to joining QMUL in 2023, James worked for 18 years at the University of Oxford, where he completed his doctoral research investigating issues related to the economic analysis of genomic diagnostic technologies for multifactorial genetic diseases in the UK NHS.
Comments